JP2004511237A - 代謝生成物の蓄積のモジュレーターについてスクリーニングするための哺乳動物２−ハイブリッドシステム - Google Patents

代謝生成物の蓄積のモジュレーターについてスクリーニングするための哺乳動物２−ハイブリッドシステム Download PDF

Info

Publication number
JP2004511237A
JP2004511237A JP2002534565A JP2002534565A JP2004511237A JP 2004511237 A JP2004511237 A JP 2004511237A JP 2002534565 A JP2002534565 A JP 2002534565A JP 2002534565 A JP2002534565 A JP 2002534565A JP 2004511237 A JP2004511237 A JP 2004511237A
Authority
JP
Japan
Prior art keywords
nucleic acid
cell
protein
chimeric protein
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002534565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511237A5 (OSRAM
Inventor
鉄　治
脇田　賢一
フランク・マコーミック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2004511237A publication Critical patent/JP2004511237A/ja
Publication of JP2004511237A5 publication Critical patent/JP2004511237A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
JP2002534565A 2000-10-13 2001-10-09 代謝生成物の蓄積のモジュレーターについてスクリーニングするための哺乳動物２−ハイブリッドシステム Pending JP2004511237A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/687,593 US6787321B1 (en) 2000-10-13 2000-10-13 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
PCT/US2001/031745 WO2002031201A2 (en) 2000-10-13 2001-10-09 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

Publications (2)

Publication Number Publication Date
JP2004511237A true JP2004511237A (ja) 2004-04-15
JP2004511237A5 JP2004511237A5 (OSRAM) 2009-01-29

Family

ID=24761035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002534565A Pending JP2004511237A (ja) 2000-10-13 2001-10-09 代謝生成物の蓄積のモジュレーターについてスクリーニングするための哺乳動物２−ハイブリッドシステム

Country Status (7)

Country Link
US (2) US6787321B1 (OSRAM)
EP (1) EP1327003B1 (OSRAM)
JP (1) JP2004511237A (OSRAM)
AT (1) ATE520788T1 (OSRAM)
AU (1) AU2001296805A1 (OSRAM)
CA (1) CA2424317A1 (OSRAM)
WO (1) WO2002031201A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2510179C (en) * 2002-12-18 2013-04-23 Chromagenics B.V. A method for improving protein production
MX2007014221A (es) * 2005-05-19 2009-02-17 Wyeth Corp Metodo para identificar compuestos que modulan la interaccion del receptor de androgeno con beta-catenina.
WO2008106087A1 (en) * 2007-02-28 2008-09-04 The Brigham And Women's Hospital, Inc. Compositions and methods for identifying factors affecting protein stability
EP2500428A3 (en) 2007-07-11 2012-12-26 Yeda Research and Development Co. Ltd. Nucleic acid construct systems capable of diagnosing or treating a cell state
WO2011019763A2 (en) * 2009-08-10 2011-02-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
WO2019099678A1 (en) 2017-11-16 2019-05-23 Synthex, Inc. Selective modulation of protein-protein interactions
WO2020232343A1 (en) * 2019-05-15 2020-11-19 Synthex, Inc. Selective degradation of proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370813A3 (en) 1988-11-25 1991-06-19 Exemplar Corporation Rapid screening mutagenesis and teratogenesis assay
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
NZ502795A (en) 1995-04-11 2001-09-28 Gen Hospital Corp Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
FR2734567B1 (fr) 1995-05-26 1997-08-08 Commissariat Energie Atomique Proteines chimeriques activant la transcription par la polymerase iii, leur utilisation pour la detection et l'analyse des interactions entre proteines, et genes codant pour lesdites proteines
USH1892H (en) 1995-07-27 2000-10-03 Pharmacia And Upjohn Company High volume nutrient based yeast two-hybrid assay for the identification of specific protein:protein interacting inhibitors
US5948620A (en) 1996-08-05 1999-09-07 Amersham International Plc Reverse two-hybrid system employing post-translation signal modulation
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
AU721549B2 (en) 1996-12-11 2000-07-06 Bristol-Myers Squibb Company Prokaryotic two-hybrid system
US5851775A (en) * 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
US5885779A (en) * 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
US6242253B1 (en) * 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same

Also Published As

Publication number Publication date
WO2002031201A2 (en) 2002-04-18
WO2002031201A3 (en) 2002-11-21
ATE520788T1 (de) 2011-09-15
US7358086B2 (en) 2008-04-15
EP1327003B1 (en) 2011-08-17
EP1327003A2 (en) 2003-07-16
CA2424317A1 (en) 2002-04-18
AU2001296805A1 (en) 2002-04-22
US20040265791A1 (en) 2004-12-30
US6787321B1 (en) 2004-09-07

Similar Documents

Publication Publication Date Title
US6737523B1 (en) Nucleic acids comprising regions of the rat PEG-3 promoter that display elevated expression in human cancer cells and uses thereof
Acsadi et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer
US20090041740A1 (en) Cancer treatment by metabolic modulations
Kohler et al. Functional definition of the mutation cluster region of adenomatous polyposis coli in colorectal tumours
WO2005001136A1 (en) Methods and compositions for modulating erythropoietin expression
JP2006508939A5 (OSRAM)
Kumagai et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements
KR20240134108A (ko) Rna-프로그램가능한 세포 편집을 위한 조성물 및 시스템 및 이의 제조 및 사용 방법
US20050158712A1 (en) Methods for purifying viral particles for gene therapy
WO2001075168A1 (en) Control of a gene induced by oxidized lipids in human artery wall cells
EP1327003B1 (en) Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
Lu et al. p53-Bad: a novel tumor suppressor/proapoptotic factor hybrid directed to the mitochondria for ovarian cancer gene therapy
EP1115877B1 (en) Polynucleotide constructs and uses thereof
JP2005525779A (ja) 核酸構築物のトランスフェクションによって、身体サンプルから細胞を特異的に検出、単離および特徴付けするための方法
Emiliusen et al. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component
JP4660486B2 (ja) ヒトアポリポ蛋白質（ａ）クリングルＬＫ６８またはＬＫ８遺伝子を有効成分として含有する抗癌治療剤及びそれを使用した癌治療方法
EP0842426B1 (en) Improvements in or relating to methods of screening substances
CN114729021B (zh) 能破坏细胞的氨基酸序列及相关核苷酸序列和相关的应用
Oh et al. Generation of fusion genes carrying drug resistance, green fluorescent protein, and herpes simplex virus thymidine kinase genes in a single cistron
US20040171035A1 (en) Methods and compositions for modulating P53 transcription factor
EP1147208A2 (en) Compositions and methods for intraductal gene therapy
AU2003245342A1 (en) Control sequences of the human corin gene
JP2004520006A (ja) ラットｐｅｇ−３プロモーターの領域を含んでなる核酸とその利用
US6982148B2 (en) Progressive elevated gene-3 (PEG-3) induces aggressive cancer phenotype and regulates angiogenesis
MX2009000976A (es) Composicion y metodo para el tratamiento de tumores.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081027

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081125

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20081125

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100106